President Joe Biden on Feb. 2 announced plans to reduce the death rate from cancer by at least 50 percent over the next 25 years, part of an effort to revive the “Cancer Moonshot” initiative to speed research and make more treatments available.
Fewer Americans are dying from the most common types of cancer, especially lung, showed a report published in The Journal of the National Cancer Institute on July 8.
AstraZeneca Plc’s drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on June 3.
Covid-19 was the primary or contributing cause of 377,883 deaths in the United States during 2021, with a particularly high toll among the elderly, according to a government report released on March 31.
Cancer deaths in the United States fell 2.2% from 2016 to 2017 – the largest single-year drop ever recorded – fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported.
An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
OncoCyte Corporation, a developer of novel tests for the early diagnosis and management of lung cancer, announced a definitive agreement to acquire Razor Genomics.
GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.
Pfizer Inc.’s once-daily oral drug Vizimpro to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration.
Cancer will claim the lives of 9.6 million people in 2018, accounting for one in eight of all deaths among men and one in 11 among women, the WHO’s cancer research agency said.